What is it about?

Cancer treatment can be challenging because conventional therapies may affect healthy cells as well as cancer cells. Enzyme-responsive drug delivery systems offer a promising approach to addressing this challenge. These systems are designed to respond to specific enzymes that are present or overexpressed in the tumour environment, triggering the release of therapeutic agents at the intended site. This article explores the principles behind enzyme-responsive drug delivery, the role of tumour-associated enzymes in activating drug release, and the potential of these systems to improve the precision of cancer treatment. It also discusses different design strategies, their therapeutic applications, and the challenges that must be addressed to translate these advanced drug delivery technologies into clinical practice.

Featured Image

Why is it important?

Improving the precision of cancer treatment is essential for maximising therapeutic benefits while minimising unwanted effects on healthy tissues. Enzyme-responsive drug delivery systems may help achieve this by using biochemical signals associated with the tumour microenvironment to control when and where drugs are released. By highlighting the relationship between tumour biology and drug delivery design, this article contributes to the understanding of targeted therapeutic approaches. Such technologies could potentially improve drug accumulation at tumour sites, enhance treatment effectiveness, and reduce systemic toxicity. Although further research and clinical validation are needed, enzyme-responsive delivery systems represent a promising direction for the development of more precise cancer therapies.

Perspectives

The future of enzyme-responsive drug delivery lies in developing increasingly selective, stable, and biocompatible systems that respond to the unique biochemical characteristics of individual tumours. Combining enzyme-sensitive drug carriers with nanotechnology, multifunctional materials, and personalised medicine approaches may offer new opportunities for improving cancer treatment. However, challenges such as variability in enzyme expression between patients, premature drug release, biological barriers, manufacturing complexity, and clinical translation must be carefully addressed. Future research should focus on validating these systems in relevant biological models, establishing their safety and efficacy, and developing scalable manufacturing strategies. Ultimately, enzyme-responsive drug delivery could contribute to a more personalised and precision-oriented approach to cancer therapy, bringing drug delivery design closer to the specific biological needs of each patient.

Akanksha Kamble

Read the Original

This page is a summary of: Biochemical Precision: Enzyme-Responsive Drug Delivery Systems in Cancer Therapy, Current Enzyme Inhibition, August 2026, Bentham Science Publishers,
DOI: 10.2174/0115734080363073250723061416.
You can read the full text:

Read

Resources

Contributors

The following have contributed to this page